Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cencora ( (COR) ) has provided an update.
Cencora reported that for its fiscal second quarter ended March 31, 2026, revenue rose 3.8% year over year to $78.4 billion, driven by growth of 2.9% in U.S. Healthcare Solutions and 13.0% in International Healthcare Solutions. The company’s GAAP diluted EPS surged to $8.40 from $3.68, largely reflecting a $1.1 billion gain tied to the February 2026 OneOncology acquisition, while adjusted diluted EPS increased 7.5% to $4.75 on stronger gross profit.
Gross profit climbed 17.3% to $3.6 billion, aided by higher margins in U.S. Healthcare Solutions from the OneOncology deal and a LIFO credit, partly offset by lower-margin GLP-1 sales and reduced antitrust settlement gains. Operating income rose 10.3% to $1.1 billion despite a more than 20% increase in operating expenses linked to integrating OneOncology, and Cencora raised its fiscal 2026 adjusted EPS guidance to $17.65–$17.90 while signaling plans to repurchase $1 billion of shares by the end of calendar 2026 amid ongoing debt paydown.
The most recent analyst rating on (COR) stock is a Buy with a $425.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
The score is primarily supported by solid operational execution and upgraded fiscal 2026 guidance, plus strong cash generation. It is held back by balance-sheet leverage and very thin margins, with near-term technical weakness (negative MACD and price below key moving averages) and a relatively high P/E with a low dividend yield.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc. is a healthcare solutions company with U.S. and international operations focused on pharmaceutical distribution and related services. Its core businesses are organized in U.S. Healthcare Solutions and International Healthcare Solutions segments, serving providers and other customers with drug distribution, specialty services, and oncology-focused offerings, including the recently acquired OneOncology platform.
Average Trading Volume: 1,350,420
Technical Sentiment Signal: Buy
Current Market Cap: $59.07B
For detailed information about COR stock, go to TipRanks’ Stock Analysis page.